We are live on ! Find out more
PBE icon

Invesco Biotechnology & Genome ETF

68 hedge funds and large institutions have $47.5M invested in Invesco Biotechnology & Genome ETF in 2016 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 30 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 8

0% more funds holding

Funds holding: 6868 (0)

0.76% less ownership

Funds ownership: 21.33%20.57% (-0.76%)

17% less capital invested

Capital invested by funds: $56.9M → $47.5M (-$9.42M)

60% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 30

Holders
68
Holders Change
Holders Change %
0%
% of All Funds
1.7%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
12
Reduced
30
Closed
8
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of Montreal
76
Bank of Montreal
Ontario, Canada
-$8K -200 Closed

PBE Hedge Fund Activity: Q4 2016 in Review

68 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q4 2016, worth a combined $47.5M — down 17% from $56.9M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new PBE positions and 8 closed out — a net gain of 2 holders — while 12 added to existing stakes and 30 trimmed.

The largest buyer was Ladenburg Thalmann Financial Services, adding an estimated $1.12M. The largest seller was Bank of America, cutting an estimated $3.28M.

  • 68 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q4 2016, unchanged from Q3 2016.
  • Funds reported $47.5M of Invesco Biotechnology & Genome ETF stock for Q4 2016, down 17% quarter-over-quarter.
  • 10 funds opened new Invesco Biotechnology & Genome ETF positions in Q4 2016 and 8 closed out, a net change of +2 holders.
  • The largest Invesco Biotechnology & Genome ETF buyer in Q4 2016 was Ladenburg Thalmann Financial Services, an estimated $1.12M added.
  • The largest Invesco Biotechnology & Genome ETF seller in Q4 2016 was Bank of America, an estimated $3.28M sold.

Based on aggregated 13F filings for Q4 2016.